These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21209445)

  • 1. Value-based insurance plus disease management increased medication use and produced savings.
    Gibson TB; Mahoney J; Ranghell K; Cherney BJ; McElwee N
    Health Aff (Millwood); 2011 Jan; 30(1):100-8. PubMed ID: 21209445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes disease management in a community-based setting.
    Berg GD; Wadhwa S
    Manag Care; 2002 Jun; 11(6):42, 45-50. PubMed ID: 12098874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value-based insurance design yields near- and long-term improvements in medication adherence.
    Collado M
    Find Brief; 2013 Mar; 16(1):1-3. PubMed ID: 23539769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care.
    Piette JD; Wagner TH; Potter MB; Schillinger D
    Med Care; 2004 Feb; 42(2):102-9. PubMed ID: 14734946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending.
    Musich S; Wang S; Hawkins K
    Popul Health Manag; 2015 Jun; 18(3):151-8. PubMed ID: 25247449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses.
    Gibson TB; Wang S; Kelly E; Brown C; Turner C; Frech-Tamas F; Doyle J; Mauceri E
    Health Aff (Millwood); 2011 Jan; 30(1):109-17. PubMed ID: 21209446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value-based insurance design for diabetes mellitus: approaches to optimal pharmacoeconomic implementation.
    Fendrick AM
    Am J Manag Care; 2010 Dec; 16(11 Suppl):S314-22. PubMed ID: 21517647
    [No Abstract]   [Full Text] [Related]  

  • 8. Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women.
    Collins RW; Anderson JW
    Prev Med; 1995 Jul; 24(4):369-74. PubMed ID: 7479627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disease Management Program - diabetes. Useful only to insurance].
    Traut V
    MMW Fortschr Med; 2005 Nov; 147(45):11. PubMed ID: 16320643
    [No Abstract]   [Full Text] [Related]  

  • 10. Does risk equalization reduce the viability of voluntary deductibles?
    van Kleef RC; Beck K; van de Ven WP; van Vliet RC
    Int J Health Care Finance Econ; 2007 Mar; 7(1):43-58. PubMed ID: 17431767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy.
    Berger J
    Am J Manag Care; 2007 Apr; 13 Suppl 2():S55-8. PubMed ID: 17417934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The estimated costs and savings of medical nutrition therapy: the Medicare population.
    Sheils JF; Rubin R; Stapleton DC
    J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
    Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes management program hikes HEDIS scores.
    Jackson RA
    Rep Med Guidel Outcomes Res; 2001 Jan; 12(1):7-9. PubMed ID: 11766718
    [No Abstract]   [Full Text] [Related]  

  • 15. Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus.
    Stuart B; Shaffer TJ; Simoni-Wastila LJ; Zuckerman IH; Quinn CC
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):195-208. PubMed ID: 17996659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes disease management: a health plan's collaborative approach.
    Mera C
    Manag Care Interface; 2004; Suppl C():4-5. PubMed ID: 15209446
    [No Abstract]   [Full Text] [Related]  

  • 17. Population management takes disease management to the next level.
    Ketner L
    Healthc Financ Manage; 1999 Aug; 53(8):36-9. PubMed ID: 10557798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications.
    Maciejewski ML; Bryson CL; Perkins M; Blough DK; Cunningham FE; Fortney JC; Krein SL; Stroupe KT; Sharp ND; Liu CF
    Am J Manag Care; 2010 Jan; 16(1):e20-34. PubMed ID: 20059288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of decreasing copayments on medication adherence within a disease management environment.
    Chernew ME; Shah MR; Wegh A; Rosenberg SN; Juster IA; Rosen AB; Sokol MC; Yu-Isenberg K; Fendrick AM
    Health Aff (Millwood); 2008; 27(1):103-12. PubMed ID: 18180484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.